Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Upcoming Result Date: Jul 26, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
7
Neutral
3
Bullish
4
Bearish
9
Neutral
3
Bullish
34
Bearish
2
Neutral
0
Bullish
30
Discovery themes featuring this stock
Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals.
The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion.
Revenue increased modestly by 2% in Q3 FY26, driven by volume growth despite challenging market conditions due to geopolitical uncertainties and a prolonged monsoon season.
Epigral reported an EBITDA margin contraction to 17% due to lower product realizations and rising raw material costs, although sustained 9-month margins were at 22%.
Forward integration efforts continue with commission of India's first Chlorotoluenes Value Chain Facility and plans for an upcoming pilot plant, reflecting a focus on expanding vertically and improving manufacturing capabilities.
Chemicals & Petrochemicals
Specialty Chemicals
5,018 Cr
High Risk
15.2
44.1
-1.9
2.3
2,114.30
806.20
Sales CAGR
Profit CAGR
ROE
ROCE
Epigral Ltd (EPIGRAL) is currently trading at 1,157.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals. The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion. Revenue increased modestly by 2% in Q3 FY26, driven by volume growth despite challenging market conditions due to geopolitical uncertainties and a prolonged monsoon season. Epigral reported an EBITDA margin contraction to 17% due to lower product realizations and rising raw material costs, although sustained 9-month margins were at 22%. Forward integration efforts continue with commission of India's first Chlorotoluenes Value Chain Facility and plans for an upcoming pilot plant, reflecting a focus on expanding vertically and improving manufacturing capabilities.
Over the past 52 weeks, Epigral Ltd has traded between a low of ₹806.20 and a high of ₹2,114.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Epigral Ltd has a market capitalization of approximately 5,017.55. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Epigral Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,017.55 Cr, Epigral Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Epigral Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Epigral Ltd is 15.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock jumped after PAT more than doubled sequentially to Rs 81.93 crore and EBITDA margin improved to 23% from 17% in Q3 FY26, alongside record quarterly revenue.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2063.65 | 5,650 Cr | 196.51 | 5.78 | 0.05 | 3.52 | 5.24 | 1.23 | ||
181.90 | 5,054 Cr | 63.30 | 2.55 | 0.16 | 4.00 | 4.35 | 2.30 | ||
1157.00 | 5,018 Cr | 15.23 | 2.26 | 0.43 | 14.94 | 14.69 | 9.47 | ||
39.62 | 4,614 Cr | 37.73 | 5.23 | 0.06 | 12.32 | 17.29 | 12.78 | ||
2455.00 | 4,327 Cr | 23.40 | 3.17 | 2.20 | 13.38 | 12.68 | 7.51 | ||
633.20 | 4,254 Cr | 29.89 | 3.98 | 0.05 | 13.31 | 14.64 | 6.81 | ||
1720.20 | 4,039 Cr | 77.11 | 5.17 | 0.12 | 5.38 | 6.63 | 5.12 | ||
| Median: 7 Co. | — | 1157.00 | 4,614 Cr | 37.73 | 3.98 | 0.12 | 12.32 | 12.68 | 6.81 |
Regulatory/Compliance Filing
Epigral Ltd informed BSE that it has made all required disclosures under Regulation 30 and is not connected with recent rises in trading volume/price, attributing the movement to market conditions.
Regulatory/Compliance Filing
Epigral Ltd informed BSE that it has made all required disclosures under Regulation 30 and has not withheld any material information; the company says recent share volume/price movement is market driven and not connected to the company.
Earnings Call/Transcript
Epigral Ltd will hold a conference call to discuss Q1 FY27 results on 2026-07-27 at 5:00 PM IST. Pre-registration and dial-in details provided via Emkay.
Earnings Call/Transcript
Epigral Limited to hold a conference call on 27 July 2026 at 5:00 PM IST to discuss Q1 FY27 results; dial-in and pre-registration details provided.
Board Meeting
Epigral Ltd notified a Board meeting on 2026-07-27 to consider and approve unaudited standalone and consolidated financial results for Q1 ended 2026-06-30 and take on record the limited review report.
Board Meeting
Epigral Ltd will hold a Board meeting on 2026-07-27 to consider and approve unaudited standalone and consolidated financial results for Q1 ended 2026-06-30 and take the limited review report on record.
